Literature DB >> 26510892

Immunomodulation of endothelial differentiated mesenchymal stromal cells: impact on T and NK cells.

Reine El Omar1,2, Yu Xiong1,2,3, Gabriel Dostert1,2, Huguette Louis2,4, Monique Gentils1,2, Patrick Menu1,2, Jean-François Stoltz1,2,3, Émilie Velot1,2, Véronique Decot1,2,3.   

Abstract

Wharton's jelly mesenchymal stromal cells (WJ-MSCs) are promising candidates for tissue engineering, as their immunomodulatory activity allows them to escape immune recognition and to suppress several immune cell functions. To date, however, few studies have investigated the effect of differentiation of the MSCs on this immunomodulation. To address this question, we sought to determine the impact of differentiation toward endothelial cells on immunoregulation by WJ-MSCs. Following differentiation, the endothelial-like cells (ELCs) were positive for CD31, vascular endothelial cadherin and vascular endothelial growth factor receptor 2, and able to take up acetylated low-density lipoproteins. The expression of HLA-DR and CD86, which contribute to MSCs immunoprivilege, was still weak after differentiation. We then co-cultured un- and differentiated MSCs with immune cells, under conditions of both direct and indirect contact. The proliferation and phenotype of the immune cells were analyzed and the mediators secreted by both ELCs and WJ-MSCs quantified. Interleukin (IL)-6, IL-1β, prostaglandin E2 and in particular indoleamine-2,3-dioxygenase expression were upregulated in ELCs on stimulation by T and NK cells, suggesting the possible involvement of these factors in allosuppression. ELCs co-cultured with T cells were able to generate CD25(+) T cells, which were shown to be of the CD4(+)CD25(+)FoxP3(+) regulatory subset. Direct contact between NK cells and ELCs or WJ-MSCs decreased the level of NK-activating receptor natural-killer group 2, member D. Moreover, direct co-culturing with ELCs stimulates CD73 acquisition on NK cells, a mechanism which may induce adenosine secretion by the cells and lead to an immunosuppressive function. Taken together, our results show that ELCs obtained following differentiation of WJ-MSCs remain largely immunosuppressive.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26510892     DOI: 10.1038/icb.2015.94

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  83 in total

1.  Endothelial cell activation and proliferation modulate NKG2D activity by regulating MICA expression and shedding.

Authors:  Annabelle Chauveau; Pierre Tonnerre; Angélique Pabois; Pierre-Jean Gavlovsky; Mathais Chatelais; Stéphanie Coupel; Béatrice Charreau
Journal:  J Innate Immun       Date:  2013-07-16       Impact factor: 7.349

2.  Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.

Authors:  Véronique Decot; Laure Voillard; Véronique Latger-Cannard; Lamia Aissi-Rothé; Pascale Perrier; Jean Francois Stoltz; Daniele Bensoussan
Journal:  Exp Hematol       Date:  2010-02-19       Impact factor: 3.084

3.  Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy.

Authors:  Giampiero La Rocca; Melania Lo Iacono; Tiziana Corsello; Simona Corrao; Felicia Farina; Rita Anzalone
Journal:  Curr Stem Cell Res Ther       Date:  2013-01       Impact factor: 3.828

Review 4.  The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).

Authors:  T L Whiteside; M Mandapathil; P Schuler
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Sylvaine You; Barbara C McGrath; Douglas R Cavener; Carmine Vacca; Ciriana Orabona; Roberta Bianchi; Maria L Belladonna; Claudia Volpi; Pere Santamaria; Maria C Fioretti; Paolo Puccetti
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

6.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.

Authors:  Katarina Le Blanc; Charlotte Tammik; Kerstin Rosendahl; Eva Zetterberg; Olle Ringdén
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

7.  The immunobiological development of human bone marrow mesenchymal stem cells in the course of neuronal differentiation.

Authors:  Chen-Tao Liu; Yu-Jia Yang; Fei Yin; Xia Wang; Xiao-He Yu; Qing-Hong Wang; Xiao-Li Wang; Min Xie
Journal:  Cell Immunol       Date:  2007-04-19       Impact factor: 4.868

8.  The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells.

Authors:  Hua Liu; David Michael Kemeny; Boon Chin Heng; Hong Wei Ouyang; Alirio J Melendez; Tong Cao
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

9.  Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC.

Authors:  Ralf Hass; Cornelia Kasper; Stefanie Böhm; Roland Jacobs
Journal:  Cell Commun Signal       Date:  2011-05-14       Impact factor: 5.712

10.  CD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cells.

Authors:  Mika Pietilä; Siri Lehtonen; Elina Tuovinen; Kaarina Lähteenmäki; Saara Laitinen; Hannu-Ville Leskelä; Antti Nätynki; Juha Pesälä; Katrina Nordström; Petri Lehenkari
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

View more
  7 in total

Review 1.  Interactions between mesenchymal stem cells and the immune system.

Authors:  Na Li; Jinlian Hua
Journal:  Cell Mol Life Sci       Date:  2017-02-18       Impact factor: 9.261

2.  Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions.

Authors:  María de Lourdes Mora-García; Rosario García-Rocha; Omar Morales-Ramírez; Juan José Montesinos; Benny Weiss-Steider; Jorge Hernández-Montes; Luis Roberto Ávila-Ibarra; Christian Azucena Don-López; Marco Antonio Velasco-Velázquez; Vianey Gutiérrez-Serrano; Alberto Monroy-García
Journal:  J Transl Med       Date:  2016-10-26       Impact factor: 5.531

3.  LL-37 boosts immunosuppressive function of placenta-derived mesenchymal stromal cells.

Authors:  Martha Oliveira-Bravo; Bruno Braga Sangiorgi; Josiane Lilian Dos Santos Schiavinato; Juliana Lott Carvalho; Dimas Tadeu Covas; Rodrigo Alexandre Panepucci; Francisco de Assis Rocha Neves; Octávio Luiz Franco; Rinaldo Wellerson Pereira; Felipe Saldanha-Araujo
Journal:  Stem Cell Res Ther       Date:  2016-12-30       Impact factor: 6.832

4.  In vivo efficacy of endothelial growth medium stimulated mesenchymal stem cells derived from patients with critical limb ischemia.

Authors:  Rida Al-Rifai; Philippe Nguyen; Nicole Bouland; Christine Terryn; Lukshe Kanagaratnam; Gaël Poitevin; Caroline François; Catherine Boisson-Vidal; Marie-Antoinette Sevestre; Claire Tournois
Journal:  J Transl Med       Date:  2019-08-09       Impact factor: 5.531

Review 5.  Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy.

Authors:  Xianyao Wang; Xing Zhao; Zhixu He
Journal:  Oncol Lett       Date:  2021-01-28       Impact factor: 2.967

6.  Characterization of an Innovative Biomaterial Derived From Human Wharton's Jelly as a New Promising Coating for Tissue Engineering Applications.

Authors:  Adrien Fayon; Deborah Helle; Gregory Francius; Jean-Baptiste Vincourt; Véronique Regnault; Dominique Dumas; Patrick Menu; Reine El Omar
Journal:  Front Bioeng Biotechnol       Date:  2022-06-13

7.  Immunomodulation by mesenchymal stem cells: Interplay between mesenchymal stem cells and regulatory lymphocytes.

Authors:  Oscar Ka-Fai Ma; Koon Ho Chan
Journal:  World J Stem Cells       Date:  2016-09-26       Impact factor: 5.326

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.